Q3 2025 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Gland Pharma Ltd (NSE:GLAND) reported a consolidated EBITDA margin of 46% for Q3 FY25, a 100 basis points increase year over year.
- The company launched 13 new molecules during the quarter, strengthening its product portfolio and positioning for growth in the US market.
- Revenue from Rest-of-the-World markets increased to 21% of total revenues in Q3 FY25, indicating successful geographic diversification.
- Gland Pharma Ltd (NSE:GLAND) received EIRs from the USFDA for its Hyderabad facilities, signifying successful closure of inspections and commitment to quality standards.
- The company has entered into promising collaborations in the biologics segment, including agreements with Dr. Reddy's Laboratories and Shanghai Henlius Biotech, expected to drive future growth.
- Revenue from the base business, excluding Cenexi, decreased by 8% year over year due to volume degrowth in key products.
- Cenexi's revenue was below estimates, impacted by reduced manufacturing activity following regulatory audits.
- The US market saw a decline in revenue due to shipping delays of key products, affecting quarterly performance.
- The Saudi contract shipments were delayed, impacting revenue estimates for the quarter.
- Cenexi's EBITDA was negative due to an unannounced inspection by the ANSM, delaying breakeven expectations to FY26.
Ladies and gentlemen, good day, and welcome to Gland Pharma Q3 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. [Ranjit Jain]. Thank you, and over to you, ma'am.
Thank you, Rhea. Good evening, everyone. We welcome you to the Gland Pharma's earnings conference call for Q3 FY25. Today, we have Mr. Srinivas Sadu, Executive Chairperson; Mr. Shyamakant Giri, Chief Executive Officer; Mr. Ravi Mitra, Chief Financial Officer from India's Office; and Mr. Alain, CEO of Cenexi, who's connected virtually from France.
We'll begin the call with business highlights from Mr. Sadu, followed by Mr. Giri, who will share his vision about the company. This will be followed by an overview of Cenexi from Mr. Alain and lastly, the group financial overview for Mr. Ravi.
Before we proceed, I would like to remind everyone that some of the statements made today will be forward-looking and are based on management's current estimates. These statements should be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
